Encode QC gates and autoverification you can defend
After connectivity works, encode QC gating and a narrow AV v1 with lab ownership, versioning, and explicit non-goals — before expanding rules.
- autoverification
- quality control
- QC gating
- lab middleware
- SOP
- laboratory supervisor
What “encode policy” means
Once orders and results move reliably through middleware, the next job is to encode laboratory policy: how QC status affects release, and which results may auto-release versus hold for review.
This is not “turn on the vendor default pack.” It is lab-authored criteria, versioned, with named approvers.
Audience: lab supervisors / QA and middleware / informatics owners.
Sequence that stays defensible
- QC gates first — failed or overdue QC blocks patient auto-release for the affected assay (or instrument), per SOP
- AV v1 narrow — analytic limits, critical holds, basic deltas on a short analyte list
- Expand after evidence — consistency rules and wider menus only after parallel validation
What to write down before configuring
- QC pass / fail / overdue → release behaviour in SOP language
- AV v1 scope by analyte (and explicit non-goals)
- Rule versions and who approved them
- Exception queue fields (which rule fired, next action)
- Critical-value path remains human-owned
- Change control for production rule edits
Failure mode
Vendor default rule pack, zero ownership. AV is on; nobody can explain a hold. Fix: lab-authored policy first; middleware implements; every rule has an approver.
FAQ
Should full AV ship in the first encode wave?
Usually no. Ship QC gates plus a narrow analyte list; expand after validation evidence.
Who approves rule versions?
Lab leadership accountable; QA typically responsible. Middleware packages rules — it does not invent clinical policy.
Related reading
- Autoverification without the anxiety
- QC that doesn’t live in a spreadsheet
- When to pause autoverification
- Middleware implementation without the project spiral
About TransLABtor
TransLABtor provides a rules layer for QC gating and AV with operational audit trails. Policy authorship stays with the laboratory. Contact.